Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clostridium difficile vaccine - Sanofi

Next Previous
Drug Profile

Clostridium difficile vaccine - Sanofi

Alternative Names: ACAM Cdiff; ACAM-CDIFF; CdVax; Clostridium difficile toxoid vaccine - sanofi pasteur

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Clostridium difficile infections

Most Recent Events

  • 01 Dec 2017 Sanofi Pasteur terminates a phase III trial for Clostridium difficile infections (prevention) in USA, Canada, Australia, Brazil, Chile, Colombia, Finland, France, Germany, South Korea, Mexico, Peru, Puerto Rico, Singapore, Sweden, Taiwan, United Kingdom, Spain, Poland, Denmark, Czech Republic, Cost Rica, Dominican Republic, Guatemala, Japan, South Korea, Panama, Peru and Philippines based on the interim analysis by the Independent Data Monitoring Committee indicating a low probability for achieving primary endpoints (IM) (NCT01887912)
  • 01 Dec 2017 Discontinued - Phase-II for Clostridium difficile infections in USA, United Kingdom (IM)
  • 01 Dec 2017 Discontinued - Phase-III for Clostridium difficile infections (Prevention) in USA, Canada, Australia, Brazil, Brazil, Chile, Chile, Colombia, Finland, France, Germany, South Korea, Mexico, Peru, Puerto Rico, Puerto Rico, Singapore, Sweden, Taiwan, United Kingdom, Spain, Poland, Denmark, Czech Republic, Costa Rica, Guatemala, Dominican Republic, Guatemala, Panama, Philippines, Japan (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top